These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21753253)

  • 1. Proteinuria in an African HIV-infected patient: effects of telmisartan.
    Ucciferri C; Falasca K; Mancino P; Pizzigallo E; Vecchiet J
    Infez Med; 2011 Jun; 19(2):125-7. PubMed ID: 21753253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
    Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
    Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
    Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
    Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
    Bichu P; Nistala R; Khan A; Sowers JR; Whaley-Connell A
    Vasc Health Risk Manag; 2009; 5(1):129-40. PubMed ID: 19436679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan treatment of refractory proteinuria in a dog.
    Bugbee AC; Coleman AE; Wang A; Woolcock AD; Brown SA
    J Vet Intern Med; 2014; 28(6):1871-4. PubMed ID: 25270397
    [No Abstract]   [Full Text] [Related]  

  • 6. Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.
    Lake JE; Seang S; Kelesidis T; Liao DH; Hodis HN; Stein JH; Currier JS
    HIV Clin Trials; 2015 Oct; 16(5):197-206. PubMed ID: 26360501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients.
    Cupisti A; Rizza GM; D'Alessandro C; Morelli E; Barsotti G
    Biomed Pharmacother; 2003; 57(3-4):169-72. PubMed ID: 12818479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies.
    Aranda P; Segura J; Ruilope LM; Aranda FJ; Frutos MA; López V; López de Novales E
    Am J Kidney Dis; 2005 Dec; 46(6):1074-9. PubMed ID: 16310573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effect of telmisartan in patients with chronic kidney disease.
    Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Node K
    Clin Exp Hypertens; 2008 Oct; 30(7):662-72. PubMed ID: 18855269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.
    Weinbergová O; Metelka R; Vymetal J; Konecný K; Kosatíková Z
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Jul; 148(1):69-73. PubMed ID: 15523550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials.
    Takagi H; Yamamoto H; Iwata K; Goto SN; Umemoto T;
    Int J Cardiol; 2013 Aug; 167(4):1443-9. PubMed ID: 22560941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
    Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S
    J Int Med Res; 2005; 33(6):677-86. PubMed ID: 16372586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine Eicosanoids in the Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial.
    Le CN; Hulgan T; Tseng CH; Milne GL; Lake JE
    PLoS One; 2017; 12(1):e0170515. PubMed ID: 28118376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan in incipient and overt diabetic renal disease.
    Schmieder RE; Bakris G; Weir MR
    J Nephrol; 2011; 24(3):263-73. PubMed ID: 21374585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renoprotective effects of telmisartan in patients with advanced chronic kidney disease.
    Tokunaga M; Kabashima N; Serino R; Shibata T; Matsumoto M; Miyamoto T; Miyazaki M; Furuno Y; Nakamata J; Fujimoto Y; Takeuchi M; Abe H; Okazaki M; Otsuji Y; Tamura M
    Clin Nephrol; 2010 Feb; 73(2):139-46. PubMed ID: 20129021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy.
    Zhang Z; Li Z; Cao K; Fang D; Wang F; Bi G; Yang J; He Y; Wu J; Wei Y; Song X
    J Hypertens; 2017 Jul; 35(7):1442-1456. PubMed ID: 28244896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
    Masuda S; Tamura K; Wakui H; Kanaoka T; Ohsawa M; Maeda A; Dejima T; Yanagi M; Azuma K; Umemura S
    Hypertens Res; 2009 Nov; 32(11):950-5. PubMed ID: 19713965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of telmisartan in an HIV+ diabetic insulin-dependent patient.
    Ucciferri C; Mancino P; Vecchiet J; Falasca K
    Int J Immunopathol Pharmacol; 2009; 22(3):853-7. PubMed ID: 19822103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan: a different angiotensin II receptor blocker protecting a different population?
    Burnier M
    J Int Med Res; 2009; 37(6):1662-79. PubMed ID: 20146864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.